These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 17638398)

  • 1. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
    Viganò A; Zuccotti GV; Martelli L; Giacomet V; Cafarelli L; Borgonovo S; Beretta S; Rombolà G; Mora S
    Clin Drug Investig; 2007; 27(8):573-81. PubMed ID: 17638398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study.
    Viganò A; Bedogni G; Manfredini V; Giacomet V; Cerini C; di Nello F; Penagini F; Caprio C; Zuccotti GV
    Clin Drug Investig; 2011; 31(6):407-15. PubMed ID: 21528939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.
    Kinai E; Hanabusa H
    AIDS Res Hum Retroviruses; 2009 Apr; 25(4):387-94. PubMed ID: 19361280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
    Calza L; Trapani F; Tedeschi S; Piergentili B; Manfredi R; Colangeli V; Viale P
    Scand J Infect Dis; 2011 Aug; 43(8):656-60. PubMed ID: 21453205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.
    Cao Y; Han Y; Xie J; Cui Q; Zhang L; Li Y; Li Y; Song X; Zhu T; Li T
    BMC Infect Dis; 2013 Jul; 13():301. PubMed ID: 23815472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
    Viganò A; Aldrovandi GM; Giacomet V; Merlo M; Martelli L; Beretta S; Luraschi P; Rombolà G; Mora S
    Antivir Ther; 2005; 10(8):917-24. PubMed ID: 16430197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proximal renal tubular dysfunction related to antiretroviral therapy among HIV-infected patients in an HIV clinic in Mexico.
    Andrade-Fuentes K; Mata-Marín JA; López-De León JI; Manjarrez-Téllez B; Ramírez JL; Gaytan-Martínez J
    AIDS Patient Care STDS; 2015 Apr; 29(4):181-5. PubMed ID: 25101526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients.
    Horberg M; Tang B; Towner W; Silverberg M; Bersoff-Matcha S; Hurley L; Chang J; Blank J; Quesenberry C; Klein D
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):62-9. PubMed ID: 19838127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M; Kaplan R; Bekker LG; Little F; Myer L
    Trop Med Int Health; 2015 Apr; 20(4):518-26. PubMed ID: 25442109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study.
    Young B; Buchacz K; Moorman A; Wood KC; Brooks JT;
    AIDS Patient Care STDS; 2009 Aug; 23(8):589-92. PubMed ID: 19591609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults?
    Badiou S; De Boever CM; Terrier N; Baillat V; Cristol JP; Reynes J
    J Infect; 2006 May; 52(5):335-8. PubMed ID: 16176835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity.
    Vrouenraets SM; Fux CA; Wit FW; Garcia EF; Furrer H; Brinkman K; Hoek FJ; Abeling NG; Krediet RT; Reiss P;
    AIDS; 2011 Nov; 25(17):2149-55. PubMed ID: 21857491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
    Aurpibul L; Cressey TR; Sricharoenchai S; Wittawatmongkol O; Sirisanthana V; Phongsamart W; Sudjaritruk T; Chokephaibulkit K
    Pediatr Infect Dis J; 2015 Apr; 34(4):392-7. PubMed ID: 25760566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction.
    Mauss S; Berger F; Schmutz G
    AIDS; 2005 Jan; 19(1):93-5. PubMed ID: 15627039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients.
    Gallant JE; Winston JA; DeJesus E; Pozniak AL; Chen SS; Cheng AK; Enejosa JV
    AIDS; 2008 Oct; 22(16):2155-63. PubMed ID: 18832879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men.
    Wever K; van Agtmael MA; Carr A
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):78-81. PubMed ID: 20173649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
    Albini L; Cesana BM; Motta D; Focà E; Gotti D; Calabresi A; Izzo I; Bellagamba R; Fezza R; Narciso P; Sighinolfi L; Maggi P; Quiros-Roldan E; Manili L; Guaraldi G; Lapadula G; Torti C
    J Acquir Immune Defic Syndr; 2012 Jan; 59(1):18-30. PubMed ID: 21992924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study.
    Judd A; Boyd KL; Stöhr W; Dunn D; Butler K; Lyall H; Sharland M; Shingadia D; Riordan A; Gibb DM
    AIDS; 2010 Feb; 24(4):525-34. PubMed ID: 20139752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.
    Jabłonowska E; Wójcik K; Piekarska A
    AIDS Res Hum Retroviruses; 2014 Apr; 30(4):363-9. PubMed ID: 24164392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
    Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Sungkanuparph S
    J Antimicrob Chemother; 2014 Aug; 69(8):2195-201. PubMed ID: 24788661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.